[Studies on the preparation of camptothecin niosomes].
OBJECTIVE
To study the non-ion surfactant vehicle (niosome) entrapped-camptothecin.


METHODS
The niosome loaded with camptothecin was prepared from Span and cholesterol using aqueous dispersion of film. The vehicles were visualised by transmission electron microscopy and sized by laser particle analyzer on a Malvern Mastersizer. An HPLC analysis method of the camptothecin was established by fluorescence detection. The entrapment efficiency of the niosomes containing camptothecin was determinated after the ultracentrifugation of the niosome. The antitumor activities of the vehicles on S180 sarcoma in mouse were studied.


RESULTS
The given niosomes were the suspension finely dispersed in aqueous solution. They were spherical vehicles with the single lamellar bilayers similar to phospholipid vehicles. The mean sizes of the vehicles were (565 +/- 6) nm. The recovery of the HPLC analysis method was 100.3% with 0.4% RSD. The entrapment efficiency of the camptothecin encapsulated by the niosome was 61%. The inhibition (%) of the niosome loaded with camptothecin on S180 sarcoma in mouse were 76.1% (P < 0.05). After the given dose the weight of the mouse of the niosome groups were 92.7% (P > 0.05) and 134.7% of blank control groups and compatothecin solution groups, respectively.


CONCLUSIONS
The camptothecin niosomes were spherical in shape and similar to phospholipid vehicles with singlelamellar bilayers. Their size distributions were narrow. Their entrapment efficiency were higher. Its antitumor activity was better than camptothecin.
Luan
Li-biao
LB
Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Zhu
Jia-bi
JB
Yu
Wei-ping
WP
Wei
Kai-bin
KB
D000180:Acrylic Resins / Q000737:chemistry; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000627:therapeutic use*; D002784:Cholesterol / Q000737:chemistry; D004195:Disease Models, Animal; D004339:Drug Compounding; D016503:Drug Delivery Systems; D051379:Mice; D009368:Neoplasm Transplantation; D010316:Particle Size; D012510:Sarcoma 180 / Q000188:drug therapy* / Q000473:pathology; D013501:Surface-Active Agents; D014407:Tumor Cells, Cultured
D000180:Acrylic Resins; D000972:Antineoplastic Agents, Phytogenic; D013501:Surface-Active Agents; C106181:SPAN polymer; D002784:Cholesterol; D002166:Camptothecin